Print
Email
Print Edition Stories
MHT's Julie Donnelly: Life science startups finding investments
MHT's Efrain Viscarolasaga: Tech companies may have to wait for stimulus funds
MHT's Marc Songini: RI plans launch of cord blood center
Mansfield-based molecular diagnostics company Primera Biosystems Inc. has secured $1.15 million of a $1.7 million new debt financing round, according to federal documents. The company is developing a proprietary nucleic acid analysis system, STAR (Scalable Target Amplification Routine), invented by Vladimir Slepnev, Primera’s chief scientific officer and co-founder.
The filing with the U.S. Securities and Exchange Commission did not mention the source of the debt financing. Previous venture investors in Primera include U.K.-based Abingworth LLP, Interwest Partners LLC of Menlo Park, Calif., Malaysian Technology Development Corp., MPM Capital, Burrill & Co. and the Invus Group.
In January of 2008, Primera took in a last round of equity financing, a Series B round worth $21 million, from the above-named investors. In October of 2007, the company brought in $2.4 million as a supplement to its $11 million Series A financing in 2005.
Primera was spun off from Providence, R.I.-based life sciences company Sention Inc. and started out based in Providence before moving to Mansfield in 2006. The company says it plans to commercialize its STAR platform and assay reagents to hospital and reference laboratories, and plans to seek regulatory approval in the future.
RSS Feeds
Comments
Please Login/Register to post comments.
No comments have been added or approved.